Stem Cells SpinWAR:SCS 25 PB Ratio is 2.67 as of Jul. 03, 2026, which is 17% above its 10-year median of 2.29. GuruFocus rates WAR:SCS with a GF Score™ of 25/100 and a GF Value™ of zł0.10 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 1,228 Biotechnology companies, Stem Cells Spin ranks better than 53.83% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-03), Stem Cells Spin's share price is zł0.40. Stem Cells Spin's Book Value per Share for the quarter that ended in Mar. 2026 was zł0.15. Hence, Stem Cells Spin's PB Ratio of today is 2.67.
Warning Sign:
Stem Cells Spin SA stock PB Ratio (=2.67) is close to 2-year high of 2.92.
The historical rank and industry rank for Stem Cells Spin's PB Ratio or its related term are showing as below:
WAR:SCS'
s PB Ratio Range Over the Past 10 Years
Min: 0.7 Med: 2.29 Max: 10.22
Current: 2.67
During the past 13 years, Stem Cells Spin's highest PB Ratio was 10.22. The lowest was 0.70. And the median was 2.29.
WAR:SCS's PB Ratio is ranked better than 53.83% of 1228
companies
in the Biotechnology industry
Industry Median: 2.97
vs WAR:SCS: 2.67
During the past 12 months, Stem Cells Spin's average Book Value Per Share Growth Rate was -8.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -5.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -3.50% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -9.40% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Stem Cells Spin was 38.50% per year. The lowest was -22.00% per year. And the median was -3.00% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Stem Cells Spin PB Ratio Related Terms
Stem Cells Spin PB Ratio Historical Data
* Premium members only.
The historical data trend for Stem Cells Spin's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Stem Cells Spin's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stem Cells Spin PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Stem Cells Spin's PB Ratio distribution charts can be found below:
* The bar in red indicates where Stem Cells Spin's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Stem Cells Spin's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Stem Cells Spin (WAR:SCS) has a PB Ratio of 2.67 as of Jul. 03, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Stem Cells Spin and its competitors. This is 17% above median its historical median of 2.29. Over the past decade, Stem Cells Spin's PB Ratio has ranged from 0.70 to 10.22. According to the industry distribution chart, Stem Cells Spin ranks #567 out of 1228 companies in the Biotechnology industry, placing it in the top 46.2%.
Is Stem Cells Spin's PB Ratio too high?
Stem Cells Spin's current PB Ratio of 2.67 is 17% above median its 10-year median of 2.29. Over the past 10 years, this metric has ranged from a low of 0.70 to a high of 10.22. The Biotechnology industry median PB Ratio is 2.97. Stem Cells Spin's value of 2.67 is 10.1% below this industry median. Based on the distribution chart, Stem Cells Spin ranks #567 out of 1228 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Stem Cells Spin has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Stem Cells Spin's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Stem Cells Spin ranks #567 out of 1228 companies for PB Ratio. This puts Stem Cells Spin in the upper half of its industry. The industry median PB Ratio is 2.97. Stem Cells Spin's value of 2.67 is 10.1% below this benchmark. Historically, Stem Cells Spin's own PB Ratio has ranged from 0.70 to 10.22 over the past decade. While the company's 10-year median is 2.29 vs. the industry median of 2.97, Stem Cells Spin has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.97, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Stem Cells Spin's current PB Ratio of 2.67 is 10.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Stem Cells Spin and its competitors. For the Biotechnology industry, the median PB Ratio is 2.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stem Cells Spin's current PB Ratio is 2.67, which is 17% above median its own 10-year median of 2.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stem Cells Spin stock overvalued right now?
Based on GuruFocus' analysis, Stem Cells Spin (WAR:SCS) is currently considered Significantly Overvalued. The stock's GF Value™ is zł0.10, compared to a current price of zł0.40 — trading 300% above its estimated fair value. The current PB Ratio is 2.67, which is 17% above median its 10-year median of 2.29 and 10.1% below the Biotechnology industry median of 2.97. Stem Cells Spin's overall GF Score™ is 25/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Stem Cells Spin (WAR:SCS), the current PB Ratio is 2.67 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stem Cells Spin (WAR:SCS) Overvalued in 2026?
Based on GuruFocus' analysis, Stem Cells Spin stock appears to be overvalued.
The current stock price of zł0.40 is trading 300% above its estimated GF Value™ of zł0.10.
GuruFocus considers Stem Cells Spin to be Significantly Overvalued.
Key valuation signals for WAR:SCS:
PB Ratio: 2.67 (17% above median its 10-year median of 2.29)
GF Value™: zł0.10 vs. price of zł0.40 (300% above fair value)
Industry Position: 10.1% below the Biotechnology median (#567 of 1228)
No single metric tells the full story. See the WAR:SCS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stem Cells Spin SA is a biotechnology company. The company is engaged in the development, production, marketing, and sale of natural regenerative products for the dermocosmetic and veterinary care markets, as well as applications for the human and veterinary medical industry. Its products include NHAC Biocervin MIC-1, Revitacell, PRS MIC-1, and Velvetyna.
25GF Score
Get the complete analysis for WAR:SCS
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:SCS has been successfully added to your 
